About Us:
Lumos Pharma is a clinical-stage biopharmaceutical company committed to identifying, developing, and commercializing life-changing therapies for patients and families living with rare diseases.
The Company's clinical development program currently focuses on rare diseases associated with growth hormone deficiencies; the first indication targeted is Moderate Pediatric Growth Hormone Deficiency (PGHD).
LUM-201 (ibutamoren) is an orally administered small molecule that promotes the endogenous secretion of Growth Hormone (GH) from the pituitary gland. LUM-201 acts as a potent agonist of the GH Secretagogue Receptor (GHSR1a). See the below video to understand LUM-201’s mechanism of action.
LUM-201 is being studied in multiple trials:
• OraGrowtH210 Trial, a multi-center, 24 Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naive to Treatment, Prepubertal Children with Growth Hormone Deficiency (PGHD).
ClinicalTrials.gov ID NCT04614337
Active; not enrolling.
• OraGrowtH212 Trial, a single site (Santiago, Chile) PK and PD Study of LUM-201 in
Children With Idiopathic Growth
Hormone Deficiency
ClinicalTrials.gov ID NCT04806854
Active; not enrolling.
• The OraGrowtH Trial: Phase 3- Upcoming
Please contact us if you are interested in being considered as a potential site for The OraGrowtH Phase 3 Trial for LUM-201 at clinical@lumos-pharma.com.
*Important Safety Information - LUM-201 investigational studies continue. LUM-201 has been generally well tolerated to date. The most frequently reported treatment-related adverse event (AE) has been increased appetite. Other common treatment-related AEs include mild elevations in liver enzymes without accompanying changes in bilirubin, joint pain/pain in the extremities, headache, fatigue, abdominal pain, and vomiting.
For more information about Lumos Pharma, please visit us at www.lumos-pharma.com. Follow @lumos-pharma on Twitter, Facebook, Instagram, Linkedin.
Address:
4200 Marathon Boulevard, Suite 200
Austin, TX 78756
Website:
Brief summary of the materials and/or video content:
LUM-201 (ibutamoren): Mechanism of Action Video (2 min video)
GH secretion is exquisitely regulated by the opposing actions of GHRH and somatostatin. There is an intrinsic pulsatility of GH release which is modulated by GH Secretagogue Receptor (GHSR); this is mediated by GH secretion reciprocally enhancing somatostatin to lower GH secretion preparing for the next secretory burst. Over the longer term there is tonic IGF-1 feedback to prevent over secretion.
This video illustrates the natural physiological release of GH in the hypothalamic/pituitary axis and then explains: 1) how LUM-201 enhances growth hormone release through GHSR agonism and 2) how orally administered tablets of LUM-201 have shown to increase the amplitude of natural endogenous pulsatile growth hormone secretion in children with PGHD.
KOL Webinar on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency (PGHD)
Lumos Pharma hosted a KOL webinar (April 2021) on LUM-201 for the treatment of PGHD .
The recorded video features presentations by KOLs in the field of pediatric endocrinology:
- Bradley S. Miller, M.D., Ph.D., University of Minnesota, discusses the currently available treatments and unmet medical needs in PGHD. He also reviews LUM-201 PK/PD data and outlines the design of the Phase 2 OraGrowtH210 Trial.
- Fernando Cassorla, M.D., University of Chile, reviews data showing how 24hr GH pulsatility responses from a subset of PGHD children helped to define the PEM (Predicative Enrichment Marker) Strategy that is used in the Phase 2 OraGrowtH210 Trial.
Media:
Watch the KOL webinar video or view the deck